Division of Radiation Biology and Molecular Cancer Therapeutics


Research in Therapeutic Radiology Results in Novel Drugs that Work When Chemotherapy Fails

Radiobiology Lab

Chang Song, Ph.D., Professor and Director
Jianling Yuan, M.D., Assistant Professor

Radiobiology of TBI 

Role of vascular function in the response of tumor and normal tissues to radiation therapy, radio-sensitization of hypoxic cells in tumorsPathophysiological changes in tumors and normal tissues by hyperthermia and mechanisms of heat damage; heat sensitization of tumors by manipulating blood flow and decreasing intra-tumor and intracellular pH.

Molecular Cancer Therapeutics Lab

Daniel Vallera, Ph.D., Professor and Director

"Our laboratory specializes in the design and development of new anti-cancer biologic agents with the goal of getting them into the clinic as quickly as possible. Typically, new hybrid proteins are synthesized by combining genes encoding cancer cell binding domains with genes encoding molecules that deliver death signals. The resulting proteins selectively bind to cancer cells, internalize the death signal, and kill the cancer cells. Thus, they provide cancer specific therapy in a manner that chemotherapeutic agents cannot. These new anti-cancer agents are primarily directed to overexpressed signal markers on the surface of cancer cells and we have successfully produced promising fusion proteins that can kill brain tumors, breast cancer, leukemia, and cells causing organ rejection.

In order to facilitate the delivery of these agents at the site of the tumor, another approach under study uses gene therapy. We are fashioning retroviruses containing our target genes and using them to infect tumor reactive T cells. The T cells have the ability to migrate to tumor and secrete the anti-cancer molecule at site where they can have the greatest effect.

Another facet of our work focuses on the use of targeting powerful beta irradiation-emitting radionuclides, to cancer cells. Certain isotopes can be conjugated to cancer cell binding antibodies in such a way that they can selectively bind to tumors and cause their regression. In this instance, internalization of these molecules into cells are unnecessary. The cross-fire effect is potent enough to destroy even large tumors and the side effects seem tolerable. Through the design and production of these new molecules we hope to not only devise urgently needed alternative cancer therapies, but to further our understanding of the intricacies of protein engineering."